Various Clinical Presentations of Uveitis Associated with Durvalumab Treatment

BACKGROUND: Immune checkpoint inhibitors (ICI) are becoming increasingly common in treating several cancer types. Durvalumab is a human IgG1 monoclonal antibody that blocks PD-L1 binding to PD-1 and CD80 and has recently been approved for the treatment of extensive-stage small-cell lung cancer (ES-S...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrabic, Nika, Fakin, Ana, Mekjavic, Polona Jaki, Janzic, Urska, Vrankar, Martina, Valentincic, Natasa Vidovic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122297/
https://www.ncbi.nlm.nih.gov/pubmed/35412706
http://dx.doi.org/10.2478/raon-2022-0007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122297/
https://www.ncbi.nlm.nih.gov/pubmed/35412706
http://dx.doi.org/10.2478/raon-2022-0007

Ejemplares similares